CCM
TARS icon

CAAS Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

CAAS Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$827K – 1389
2020
Q4 		$827K Buy
+20,000
New +$570K 0.01% 637

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

CAAS Capital Management's TARS Position: Q1 2021 in Review

CAAS Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2021, closing a stake of 20,000 shares — an estimated $827K sold.

CAAS Capital Management first reported a position in TARS in Q4 2020 and held it in 1 quarter. The position peaked at $827K in Q4 2020. 41 funds tracked by Wall St. Rank hold TARS as of Q1 2021.

  • CAAS Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 20,000 Tarsus Pharmaceuticals shares in Q1 2021, an estimated $827K.
  • CAAS Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Tarsus Pharmaceuticals position peaked at $827K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.